Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?

Hodul PJ, Strosberg JR, Kvols LK.

Cancer Control. 2008 Oct;15(4):314-21. Review.

2.

Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF.

Cancer. 2009 Feb 15;115(4):741-51. doi: 10.1002/cncr.24065.

3.

Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ.

Ann Surg. 2008 Mar;247(3):490-500. doi: 10.1097/SLA.0b013e31815b9cae.

PMID:
18376195
4.

Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?

Teh SH, Deveney C, Sheppard BC.

Am J Surg. 2007 May;193(5):610-3; discussion 613.

PMID:
17434366
5.

Neuroendocrine tumors of the pancreas.

Ehehalt F, Saeger HD, Schmidt CM, Grützmann R.

Oncologist. 2009 May;14(5):456-67. doi: 10.1634/theoncologist.2008-0259. Epub 2009 May 1. Review.

6.

Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.

Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS.

J Am Coll Surg. 2007 Oct;205(4):558-63. Epub 2007 Aug 3.

PMID:
17903729
7.

Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.

Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL, Nava HR, Gibbs JF.

Ann Surg Oncol. 2002 Nov;9(9):855-62.

PMID:
12417506
8.

Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review.

Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M.

Neuroendocrinology. 2011;93(4):223-9. doi: 10.1159/000324770. Epub 2011 Feb 25. Review.

9.

Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases.

Gao C, Fu X, Pan Y, Li Q.

Dig Surg. 2010 Aug;27(3):197-204. doi: 10.1159/000253871. Epub 2010 Jun 22.

PMID:
20571266
10.

Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.

Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Büchler MW.

Br J Surg. 2008 May;95(5):627-35. doi: 10.1002/bjs.6051.

PMID:
18306152
11.

Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.

Bahra M, Jacob D, Pascher A, Plockinger U, Kristiansen G, Neuhaus P, Langrehr JM.

J Gastroenterol Hepatol. 2007 Jun;22(6):930-5. Epub 2007 Apr 19.

PMID:
17489964
12.

Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.

Crippa S, Partelli S, Zamboni G, Scarpa A, Tamburrino D, Bassi C, Pederzoli P, Falconi M.

Surgery. 2014 Jan;155(1):145-53. doi: 10.1016/j.surg.2013.08.002.

PMID:
24646958
13.

Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.

Birnbaum DJ, Turrini O, Vigano L, Russolillo N, Autret A, Moutardier V, Capussotti L, Le Treut YP, Delpero JR, Hardwigsen J.

Ann Surg Oncol. 2015 Mar;22(3):1000-7. doi: 10.1245/s10434-014-4016-8. Epub 2014 Sep 5.

PMID:
25190116
14.

Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.

Kondo NI, Ikeda Y, Maehara S, Sugimoto R, Nishiyama K, Sakaguchi Y.

JOP. 2013 Jul 10;14(4):415-22. doi: 10.6092/1590-8577/1291.

15.

Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms.

Cho CS, Labow DM, Tang L, Klimstra DS, Loeffler AG, Leverson GE, Fong Y, Jarnagin WR, D'Angelica MI, Weber SM, Blumgart LH, Dematteo RP.

Cancer. 2008 Jul 1;113(1):126-34. doi: 10.1002/cncr.23523.

16.

Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.

Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2012 Mar;19(3):966-72. doi: 10.1245/s10434-011-1997-4. Epub 2011 Aug 16.

PMID:
21845496
17.

Surgery in malignant pancreatic neuroendocrine tumors.

Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR.

J Surg Oncol. 2007 Oct 1;96(5):397-403.

PMID:
17469119
18.

Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it?

Abu Hilal M, McPhail MJ, Zeidan BA, Jones CE, Johnson CD, Pearce NW.

JOP. 2009 May 18;10(3):276-9.

19.

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS.

Surgery. 2013 Oct;154(4):785-91; discussion 791-3. doi: 10.1016/j.surg.2013.07.004.

PMID:
24074416
20.

[Surgery for pancreatic neuroendocrine tumors].

Shibata C, Egawa S, Motoi F, Morikawa T, Naitoh T, Unno M, Sasaki I.

Nihon Geka Gakkai Zasshi. 2012 Nov;113(6):502-6. Japanese.

PMID:
23330458

Supplemental Content

Support Center